Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results

To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment. Multicenter, randomized clinical trial. Patients (n = 1107) who were followed up during year 2 among...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology (Rochester, Minn.) Vol. 127; no. 4S; p. S135
Main Authors:	Martin, Daniel F, Maguire, Maureen G, Fine, Stuart L, Ying, Gui-Shuang, Jaffe, Glenn J, Grunwald, Juan E, Toth, Cynthia, Redford, Maryann, Ferris, 3rd, Frederick L
Format:	Journal Article
Language:	English
Published:	United States 01.04.2020
Subjects:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Bevacizumab - therapeutic use Choroidal Neovascularization - diagnosis Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology Female Fluorescein Angiography Humans Intravitreal Injections Male Middle Aged Ranibizumab - therapeutic use Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology
ISSN:	1549-4713, 1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!